HER2+ Early-Stage Breast Cancer with Ruth O'Regan, MD Case 1
HER2+ Early-Stage Breast Cancer with Ruth O'Regan, MD
Case Scenario 1:
- This is a post-menopausal 58-year-old female in whom a mass was discovered in her right breast during her annual mammography.
- Her gynecologist referred her to a breast surgeon; results of her biopsy revealed 3 cm ductal carcinoma
- Pathology shows: ER & PR–, HER2 IHC 3+
- Clinical staging; T2aN1M0
- Her surgeon discussed the patient’s case at the Breast Tumor Board and it was suggested that the patient be referred to a medical oncologist for consideration of HER2-targeted neoadjuvant therapy.
- The surgeon shared his opinion with the patient who agreed to go to the medical oncologist to discuss her options.
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020Podcast
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
